Xencor, Inc. (XNCR)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 22.46 |
| Open | 22.54 |
| Bid | 22.96 x 100 |
| Ask | 23.06 x 200 |
| Day's Range | 22.30 - 23.47 |
| 52 Week Range | 16.49 - 28.96 |
| Volume | |
| Avg. Volume | 731,684 |
| Market Cap | 1.42B |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.17 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.27 |
Simply Wall St.Xencor First Quarter 2024 Earnings: Misses Expectations
Xencor ( NASDAQ:XNCR ) First Quarter 2024 Results Key Financial Results Revenue: US$12.8m (down 33% from 1Q 2023). Net...
- GuruFocus.com
Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
Comprehensive Analysis of Financial Performance and Strategic Initiatives
Business WireXencor Reports First Quarter 2024 Financial Results
PASADENA, Calif., May 09, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.
© 2024 Yahoo. All rights reserved.